NDATOPICALLOTION
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
4/8 — Partial
CLOBEX (clobetasol propionate) by Galderma is lotion, 0. First approved in 2003.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLOBEX is a topical corticosteroid lotion containing clobetasol propionate 0.05%, a potent anti-inflammatory and antipruritic agent used to treat inflammatory skin conditions. It works by inhibiting phospholipase A2, thereby reducing the release of inflammatory mediators such as prostaglandins and leukotrienes. The mechanism involves induction of lipocortins that control arachidonic acid biosynthesis.
LOE Approaching
Product is approaching loss of exclusivity, signaling a transition phase with likely reductions in brand investment and commercial team expansion.
Mechanism of Action
Lotion, 0.05% has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids in general is unclear. However, corticosteroids are thought to act by induction of phospholipase A 2 inhibitory proteins, collectively called…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (19)
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Started Dec 2022
60 enrolled
Cataracts Infantile
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Started Nov 2022
70 enrolled
Alopecia Areata
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Started Jun 2020
250 enrolled
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Started Jun 2020
215 enrolled
Cataract
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Started Jul 2013
28 enrolled
Plaque Psoriasis
Worked on CLOBEX at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.